Compare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 27.6 - View Chart
P/BV x 6.3 2.4 264.6% View Chart
Dividend Yield % 0.7 0.7 102.5%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-19
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589679 234.1%   
Low Rs1,232375 328.2%   
Sales per share (Unadj.) Rs417.5121.1 344.6%  
Earnings per share (Unadj.) Rs56.313.4 420.9%  
Cash flow per share (Unadj.) Rs64.720.7 312.8%  
Dividends per share (Unadj.) Rs12.702.75 461.8%  
Dividend yield (eoy) %0.90.5 172.6%  
Book value per share (Unadj.) Rs292.9172.6 169.7%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 77.7%   
Avg P/E ratio x25.139.4 63.6%  
P/CF ratio (eoy) x21.825.5 85.5%  
Price / Book Value ratio x4.83.1 157.7%  
Dividend payout %22.620.6 109.7%   
Avg Mkt Cap Rs m168,6531,264,650 13.3%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m9,17159,671 15.4%   
Avg. sales/employee Rs ThNM16,608.1-  
Avg. wages/employee Rs ThNM3,409.6-  
Avg. net profit/employee Rs ThNM1,833.8-  
INCOME DATA
Net Sales Rs m49,915290,659 17.2%  
Other income Rs m1,64510,255 16.0%   
Total revenues Rs m51,561300,914 17.1%   
Gross profit Rs m8,48263,076 13.4%  
Depreciation Rs m1,00617,533 5.7%   
Interest Rs m6715,553 12.1%   
Profit before tax Rs m8,45150,246 16.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m1,6066,009 26.7%   
Profit after tax Rs m6,73132,093 21.0%  
Gross profit margin %17.021.7 78.3%  
Effective tax rate %19.012.0 158.9%   
Net profit margin %13.511.0 122.1%  
BALANCE SHEET DATA
Current assets Rs m27,062310,692 8.7%   
Current liabilities Rs m15,324173,396 8.8%   
Net working cap to sales %23.547.2 49.8%  
Current ratio x1.81.8 98.6%  
Inventory Days Days6799 67.2%  
Debtors Days Days41112 37.0%  
Net fixed assets Rs m12,610232,477 5.4%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m34,490411,691 8.4%   
Net worth Rs m35,027414,091 8.5%   
Long term debt Rs m1,21215,226 8.0%   
Total assets Rs m54,387646,938 8.4%  
Interest coverage x13.610.0 135.4%   
Debt to equity ratio x00 94.1%  
Sales to assets ratio x0.90.4 204.3%   
Return on assets %13.65.8 233.9%  
Return on equity %19.27.8 248.0%  
Return on capital %24.910.2 244.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56366,025 9.9%   
Fx outflow Rs m3,01238,610 7.8%   
Net fx Rs m3,55227,415 13.0%   
CASH FLOW
From Operations Rs m7,25921,965 33.0%  
From Investments Rs m1,864-6,813 -27.4%  
From Financial Activity Rs m-9,273-27,305 34.0%  
Net Cashflow Rs m-150-8,442 1.8%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 19, 2019 03:35 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - BIOCON COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS